As the UK’s leading AI and machine learning technology company, BenevolentAI wants to use this blog to share its thoughts, insight and predictions.
Discovering and developing new drugs is difficult. Very difficult indeed. The cost of developing a new medicine, when you factor in the costs of all those projects which fail before getting to market, is increasing and is Very Large Indeed so what can be done to get us out of this situation?
Initiated after the first Artificial Intelligence (AI) in Bioscience Symposium in 2016, the special interest group on AI in Biomedicine aims at stimulating debate and encouraging collaboration between experts in life science and AI.
Recently we welcomed the news that we have officially selected a study name for BenevolentAI's first clinical trial.